Quintiles Transitional Holdings Inc. (NYSE:Q) Director John Connaughton sold 1,030,429 shares of the firm’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $94.87, for a total value of $97,756,799.23. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Quintiles Transitional Holdings Inc. (Q) traded up 0.04% on Friday, hitting $94.26. The stock had a trading volume of 452,744 shares. Quintiles Transitional Holdings Inc. has a 52-week low of $70.10 and a 52-week high of $99.95. The company has a market cap of $20.41 billion, a P/E ratio of 273.22 and a beta of 0.63. The stock’s 50-day moving average is $93.80 and its 200-day moving average is $86.86.

Quintiles Transitional Holdings (NYSE:Q) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $1.09 EPS for the quarter, beating the consensus estimate of $1.05 by $0.04. The firm had revenue of $1.97 billion during the quarter, compared to the consensus estimate of $1.96 billion. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 14.23%. The company’s quarterly revenue was up 68.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.93 earnings per share. Analysts expect that Quintiles Transitional Holdings Inc. will post $4.58 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Quintiles Transitional Holdings Inc. (Q) Director John Connaughton Sells 1,030,429 Shares” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/22/quintiles-transitional-holdings-inc-q-director-john-connaughton-sells-1030429-shares.html.

Several research firms recently weighed in on Q. Barclays PLC set a $100.00 price objective on Quintiles Transitional Holdings and gave the company a “buy” rating in a report on Friday, August 4th. Zacks Investment Research lowered Quintiles Transitional Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Jefferies Group LLC reaffirmed a “hold” rating and set a $94.00 target price on shares of Quintiles Transitional Holdings in a research report on Friday, August 4th. Stifel Nicolaus reaffirmed a “hold” rating and set a $92.00 target price (up from $87.00) on shares of Quintiles Transitional Holdings in a research report on Friday, August 4th. Finally, William Blair raised Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $70.10 to $93.42 in a research report on Friday, August 4th. Eleven research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $92.44.

Several large investors have recently modified their holdings of Q. ProShare Advisors LLC bought a new position in shares of Quintiles Transitional Holdings during the first quarter valued at about $229,000. Strs Ohio raised its stake in shares of Quintiles Transitional Holdings by 2.0% during the first quarter. Strs Ohio now owns 8,594 shares of the medical research company’s stock valued at $692,000 after acquiring an additional 167 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Quintiles Transitional Holdings by 15.7% during the first quarter. Russell Investments Group Ltd. now owns 50,658 shares of the medical research company’s stock valued at $4,080,000 after acquiring an additional 6,865 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Quintiles Transitional Holdings by 1.1% during the first quarter. American Century Companies Inc. now owns 11,719 shares of the medical research company’s stock valued at $944,000 after acquiring an additional 128 shares during the last quarter. Finally, Suntrust Banks Inc. raised its stake in shares of Quintiles Transitional Holdings by 24.9% during the first quarter. Suntrust Banks Inc. now owns 7,101 shares of the medical research company’s stock valued at $570,000 after acquiring an additional 1,414 shares during the last quarter. 91.34% of the stock is owned by hedge funds and other institutional investors.

Quintiles Transitional Holdings Company Profile

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.